Abstract Library

#3171 Prognostic and diagnostic value of serum 5-HIAA in well-differentiated neuroendocrine neoplasms

Introduction: There are only few studies on the diagnostic value of serum 5HIAA as compared to the 24-hours urinary sampling method and a lack of evidence on the prognostic significance of its serum levels, as well as the markers' ability to predict changes in disease status.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Wedin M

Authors: Wedin M, Mehta S, Angerås-Kraftling J, Wallin G, Daskalakis K,

Keywords: biomarker, serum 5HIAA, well-differentiated NEN,

#3047 Functional Consequence of β-Arrestin 1 Gene Knock-Out in Pancreatic Neuroendocrine Tumor Cell Line BON-1

Introduction: An important limiting factor influencing treatment efficacy of neuroendocrine tumors (NETs) with somatostatin analogs (SSA) is the availability of somatostatin receptors (SSTR) on NETs. While downregulation or altered pattern of SSTR expression are important considerations, receptor internalization/desensitization by β-arrestins may be a crucial contributing factor. Interestingly, our previous study showed a preferential higher expression of β-arrestin 1 (ARRB1), in gastroenteropancreatic NETS (GEP-NETs) compared to pituitary adenomas.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Iyer A

Authors: Iyer A, Vriens J, Dogan-Oruç F, van Koetsveld P, Hofland L,

Keywords: β-arrestin 1, CRISPR-Cas9, BON-1, knock-out, SSTR, SSA, Pan-NET,

#2283 Ultra-Deep Targeted Resequencing Reveals Recurrent DAXX and CYFIP2 Mutations and Implicates Novel Pathways in Pancreatic Neuroendocrine Tumors

Introduction: Recent studies in pancreatic neuroendocrine tumors have identified mutations in DAXX/ATRX, MEN1, and genes involved in the phosphoinositide-3-kinase/Akt/mammalian target of rapamycin (PI3K-Akt-mTOR) pathway. However, these studies focused on abundant mutations.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Vandamme T

Authors: Vandamme T, Beyens M, Van Camp G, Boons G, Hofland L,

Keywords: pancreatic neuroendocrine tumors, PNET, genetics, tumor heterogeneity, hotspot mutations,

#1854 VHL Genotype Is Associated with Pancreatic Neuroendocrine Tumors (PNETs) Phenotype in Patients with Von Hippel-Lindau Disease (VHLD)

Introduction: 8-20% of patients with VHLD develop PNETs. However, there are no markers for PNETs progression in VHLD patients. The type of mutation in VHL gene is associated with clinical phenotype of VHLD.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Tirosh A

Authors: Tirosh A, Shell J, Keutgen X, Sadowski S, Green P,

Keywords: VHL, mutation, prognosis,

#1723 Evaluation of the Somatostatin and CXCR4 Chemokine Receptor Expression in Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN) of Different Origin

Introduction: Somatostatin receptors (SSTR) are known for their overexpression in well-differentiated GEP-NEN, whereas the chemokine receptor CXCR4 is considered to be present mainly in highly proliferative and advanced tumors.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lupp A

Authors: Mai R, Kaemmerer D, Sänger J, Neubauer E, Schulz S,

Keywords: somatostatin receptor, CXCR4,